Back to Search
Start Over
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2002 Dec; Vol. 41 (12), pp. 1118-23. - Publication Year :
- 2002
-
Abstract
- Objective: We attempted to evaluate the feasibility (therapeutic efficacy, tolerance, and clinical courses after treatment) of pirfenidone, an anti-fibrotic drug for patients with chronic pulmonary fibroses such as idiopathic pulmonary fibrosis (IPF).<br />Methods: Open-label one-year treatment for compassionate-use.<br />Patients or Materials: Oral pirfenidone (40 mg/kg body weight) was administered to 8 patients with advanced IPF and 2 with interstitial pneumonia associated with diffuse systemic sclerosis. The plasma concentration of the drug was serially followed. Radiographic scores, pulmonary functions, and arterial blood oxygen pressure were compared at three time points: at one-year before treatment, at the time of entry, and at one-year after entry.<br />Results: While pirfenidone did not show a definite therapeutic effect on overall survival (2 years after entry). During one-year treatment, there was no significant deterioration in terms of chest radiographic scores and arterial oxygen pressure, and the drug was well tolerated with minimal adverse effects within the ranges observed in this study, plasma pirfenidone concentrations did not seem to relate to the appearance of adverse effects or differences in therapeutic effects.<br />Conclusion: The feasibility of Pirfenidone as a therapeutic drug was confirmed for patients with advanced pulmonary fibrosis.
- Subjects :
- Aged
Anti-Inflammatory Agents, Non-Steroidal adverse effects
Anti-Inflammatory Agents, Non-Steroidal blood
Blood Gas Analysis
Chronic Disease
Feasibility Studies
Humans
Lung Diseases, Interstitial blood
Lung Diseases, Interstitial diagnosis
Male
Middle Aged
Pulmonary Fibrosis blood
Pulmonary Fibrosis diagnosis
Pyridones adverse effects
Pyridones blood
Radiography, Thoracic
Respiratory Function Tests
Scleroderma, Systemic complications
Time Factors
Treatment Outcome
Anti-Inflammatory Agents, Non-Steroidal therapeutic use
Lung Diseases, Interstitial drug therapy
Pulmonary Fibrosis drug therapy
Pyridones therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0918-2918
- Volume :
- 41
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 12521199
- Full Text :
- https://doi.org/10.2169/internalmedicine.41.1118